{"id":2758,"date":"2017-02-08T00:04:15","date_gmt":"2017-02-08T00:04:15","guid":{"rendered":"http:\/\/www.medicalmarijuanainc.com\/?p=20518"},"modified":"2017-02-08T00:04:15","modified_gmt":"2017-02-08T00:04:15","slug":"real-scientific-hemp-oil-authorized-anvisa-brazil-import-alzheimers-patient","status":"publish","type":"post","link":"https:\/\/medicalmarijuanainc.com\/2017\/02\/08\/real-scientific-hemp-oil-authorized-anvisa-brazil-import-alzheimers-patient\/","title":{"rendered":"Real Scientific Hemp Oil\u2122 Authorized by ANVISA in Brazil for Import by Alzheimer\u2019s Patient"},"content":{"rendered":"
HempMeds\u00ae Brasil, a Medical Marijuana, Inc. portfolio company and the local distribution branch for Medical Marijuana, Inc. products in Brazil, announced that the company has shipped Real Scientific Hemp Oil\u2122 or RSHO\u2122 to a patient in Brazil suffering from Alzheimer\u2019s disease.<\/p>\n
The patient first received a prescription from their doctor for the use of CBD before applying to Brazil\u2019s national health agency ANVISA for import approval. This authorization marks the first instance that ANVISA has allowed the import of RSHO\u2122 to specifically help a patient combat the symptoms of Alzheimer\u2019s disease. This development comes nearly two years after HempMeds\u00ae Brasil became the first company to offer legal cannabis products to Brazil as prescription medications for specific conditions.<\/p>\n
Laws and regulations governing CBD hemp oil differ between the U.S. and Brazil. In the United States, CBD oil products derived from hemp are legal to purchase in all 50 states but are not approved by the FDA as a treatment for any disease. However, in Brazil, CBD hemp oil is regulated as a medication. Qualifying patients must get a prescription from their doctor and individual approval from ANVISA in order to import CBD oil products.<\/p>\n
\u201cWe once again commend the Brazilian government for responding to the humanitarian interests of its people by allowing them access to CBD hemp oil products that can treat the symptoms of conditions with no known cure or limited treatment options,\u201d said Dr. Stuart Titus, <\/span>CEO of Medical Marijuana, Inc<\/span><\/a>. \u201cOur firm remains excited about the future for CBD based products to enter clinical trials for this and other neurological indications.\u201d<\/span><\/p>\n Alzheimer\u2019s disease is the most common form of dementia, which is characterized by problems with memory, thinking, and behavior. Alzheimer\u2019s disease is degenerative and worsens over time as the disease causes more damage to the brain. In addition to memory loss, Alzheimer\u2019s symptoms include difficulty solving problems and completing tasks, changes in personality and communication, and confusion over people and places.<\/p>\n The medical industry is desperate for a reliable treatment for the disease, but so far, pharmaceuticals are only effective in treating symptoms, not the disease itself. The U.S. government owned patent on cannabinoids, <\/span>patent 6,630,507<\/span><\/a>, <\/span>Cannabinoids as antioxidants and neuroprotectants<\/span><\/em> acknowledges the potential of cannabinoids protecting the brain from degenerative damage. The patent covers all cannabinoids for this use, both naturally occurring and synthetic.<\/span><\/p>\n \u201cTreatment solutions for neurological diseases like Alzheimer\u2019s and Parkinson\u2019s are desperately needed because of the difficulty in developing pharmaceuticals that can pass the blood-brain barrier, a specialized system of cells that allow nutrients in the brain while preventing harmful substances from passing through,\u201d added Dr. Titus. \u201cCannabinoids like CBD, however, can pass through the blood-brain barrier and affect cannabinoid\/other receptors in the brain.\u201d<\/p>\n It has been estimated that in 2045, the elderly population in Brazil will surpass the child population. As the aging population increases, there will be a further increase in age-related conditions, such as Alzheimer\u2019s disease. About one million people currently have been diagnosed with some form of dementia in Brazil. However, it is thought that <\/span>more than three quarters<\/span><\/a> of the cases in the country go undiagnosed.<\/span><\/p>\n Even once Alzheimer\u2019s disease is diagnosed, treatment options are restricted to the symptoms of the disease, as there is no currently accepted preventative or cure for the disease. Today, nearly 44 million people worldwide suffer from Alzheimer\u2019s disease or related dementia, costing an estimated <\/span>$605 billion<\/span><\/a> or 1 percent of the world\u2019s GDP just to address these symptoms.<\/span><\/p>\n Keep up to date on developments with the Medical Marijuana, Inc. portfolio of companies by following <\/span>our news feed<\/span><\/a>.<\/span><\/p>\n